"The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly. The pill is 25 milligrams of semaglutide, the same active ingredient in injectable Wegovy and Ozempic, and will be sold under the brand name Wegovy. Novo already sells an oral semaglutide for type 2 diabetes, Rybelsus."
"A 64-week, late-stage study showed participants who took 25 mg of oral semaglutide once daily lost an average of 16.6% of their body weight, compared with 2.7% for those on a placebo. The pill was approved for chronic weight management in adults with obesity or overweight and at least one related health condition, broadening the potential patient pool at a time when insurers, employers and governments are wrestling with spiraling healthcare costs related to obesity."
FDA approval of 25 mg oral semaglutide (Wegovy) grants a new daily-pill treatment option for chronic weight management in adults with obesity or overweight plus at least one related health condition. A 64-week late-stage trial showed average weight loss of 16.6% with the pill versus 2.7% for placebo. The approval leverages Novo Nordisk's existing oral semaglutide experience and could expand the patient pool significantly. U.S.-listed Novo shares rose 8% while Eli Lilly shares fell 1%. The decision comes amid intense competition and a global obesity-treatment market forecast near $150 billion annually.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]